The year 2025 is going really well.

Best trade was $MSTR (-7,92 %) at 303.

Now make up all the deficit of $SAVA (-10,9 %) cassava!

Lilium still has desire for life!

Conversion prepared with remaining cash...

Act/ETF/CRY

40/40/20

50/30/20

50/30/10

How would you allocate stock/ETF/crypto?

And yes I still change the crypto exchange...

Cassava Sciences $SAVA (-10,9 %)
and the fraud in the development of Alzheimer's drugs

Cassava Sciences $SAVA (-10,9 %) a biopharmaceutical company based in Austin, Texas, focuses on the development of innovative therapies and diagnostics for neurodegenerative diseases, particularly Alzheimer's disease. The company specializes in two main projects:

• Simufilaman oral drug that aims to inhibit the altered protein filamin A (FLNA) in the brain of Alzheimer's patients. This stabilization is intended to prevent both neurodegeneration(1) as well as neuroinflammation(2) should be reduced.

• SavaDxA diagnostic product developed to detect Alzheimer's disease from a blood sample. The aim of this test is to diagnose Alzheimer's early and facilitate monitoring of the disease.

Failure of phase 3 trials of simufilam:

• The results of the ReThink ALZ Phase 3 study were very disappointing, as the drug simufilam failed to meet the pre-defined co-primary, secondary and exploratory endpoints. It showed no significant effect on either cognitive or functional decline in patients with mild to moderate Alzheimer's disease compared to a placebo.
• Due to this failure Cassava Sciences decided to also discontinue the second Phase 3 study (ReFocus-ALZ) and an open-label extension study.

• The news about the studies caused Cassava Sciences' share price to plummet by more than 80%.

• Cassava Sciences has long been accused of data manipulation for some time. In particular, there are allegations that clinical results from earlier studies, such as the Phase 2b studywere deliberately distorted in order to exaggerate the efficacy of simufilam. The SEC has charged Cassava Sciences and individual management, including founder and former CEO Remi Barbierfor making misleading statements about the results of these studies.

• In addition to the legal allegations, the study design is also being criticized. In particular, it should be emphasized that the cognitive decline in the placebo group of the ReThink-ALZ study was less pronounced than in previous Alzheimer's studies. This made it difficult to interpret the results and could indicate that external factors influenced the study results.

Challenges in Alzheimer's research

• The development of new drugs against Alzheimer's disease is associated with high risks, as demonstrated by the failure of simufilam impressively illustrates. Alzheimer's poses an enormous challenge for research due to the complex pathophysiology of the disease.

Future prospects

• Despite the setback with simufilam Cassava Sciences continues to pursue the development of SavaDxwhich could potentially revolutionize the early detection and monitoring of Alzheimer's disease. However, to be successful in the long term, the company will not only have to address the methodological weaknesses of its studies, but also rebuild the trust damaged by the legal disputes.

What happened there 😅 $SAVA (-10,9 %)

$SAVA (-10,9 %) I find it very interesting

Two shares in short check ⬇️

The first company we are talking about is Clean Energy Fuels.

What is Clean Energy Fuels and what does it do?

Clean Energy Fuels is a renewable energy company. The company focuses on the procurement and distribution of renewable natural gas (RNG) and conventional natural gas in the form of compressed natural gas (CNG) and liquefied natural gas (LNG) for transportation markets in the United States and Canada. The company focuses on developing, owning and operating RNG projects for dairy and other animal waste, as well as supplying RNG to its heavy and medium commercial transportation customers. The company also designs and builds, and operates and maintains, public and private vehicle fueling stations in the United States and Canada; sells and services compressors and other equipment used in RNG production and at fueling stations; transports and sells CNG and LNG through virtual natural gas pipelines and interconnectors; sells federal, state and local environmental credits it earns through the sale of RNG as vehicle fuel

How many employees does the company have: 🙋🏽‍♂️🙋🏻‍♀️

Currently, Clean Energy Fuels has a total of approximately 500 employees.

Foundation:

Clean Energy Fuels was founded in 2001.

Market capitalization: 🏦

Currently, the company has a market capitalization of around 860 million euros.

Dividend yield:

The company does not yet pay dividends to its shareholders.

Strengths of Atkie: 📈

• The majority of analysts following the stock recommend its purchase or consider the stock.
• The gap between the current price and the average price target of analysts following the company is relatively large, suggesting significant potential appreciation.

Weaknesses of the share: 📉

• In general, the fundamentals of this company are of poor quality for a medium to long-term investment horizon.
• Forecasts regarding group sales have recently been revised downward. This trend in expectations indicates pronounced pessimism among analysts regarding the company's future sales.
• Over the past 12 months, analysts have regularly revised their earnings estimates downward.
• The company does not pay a dividend to its shareholders

How does the stock look from a chart perspective? (USD converted into euros) 📈📉

Let's take a look at the company's chart. The share price is currently at €3.97. We are also currently above the support zone at 3.60€. This must be kept in mind in any case. The share is slowly heading for the first resistance. This lies at just under €4.08. This resistance zone must be sustainably broken through to run to the next resistance. This resistance is at 4.60€. If this is also taken out, the share has the next zone at 5.25€. This resistance is very very important, because after that there is room to go up. In any case, I am now very curious how it continues here with the share charttechnisch. I hope times the support zone below will now hold and the share attacks the first resistances.

The second company we are looking at is Cassavas Sciences: $SAVA (-10,9 %)

What is and does Cassava Sciences: 🧐

Cassava Sciences is a clinical stage biotechnology company. The company is primarily focused on developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's disease. The company develops pharmaceutical product candidates that provide improvements for patients and healthcare professionals. The company's products include simufilam and SavaDx. Its lead therapeutic product candidate, simufilam, is a small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. The company is conducting a Phase III program with simufilam in patients with mild to moderate Alzheimer's dementia. Its product candidate, SavaDx, is an early-stage program focused on detecting Alzheimer's from a small blood sample. SavaDx is designed as an antibody-based detection system for altered filamin A.

How many people does the company employ: 🙋🏽‍♂️🙋🏻‍♀️

Currently, Cassava Sciences has a total of just around 30 employees.

Foundation:

The company was founded in May 1998 by Remi Barbier and Barry M. Sherman and is headquartered in Austin, TX. Headquarters, USA.

Market capitalization: 🏦

Currently, the company has a market capitalization of around 920 million euros.

Dividend yield:

The company does not yet pay dividends to its shareholders.

Strengths of the share: 📈

• The gap between the current price and the average price target of analysts following the company is relatively large, suggesting significant potential upside.
• The average price target of analysts following the stock has been revised upward significantly over the past four months.
• For the year just ended, analysts have regularly revised their revenue expectations for the company upward.

Weaknesses of the share: 📉

• The company does not pay dividends to its shareholders
• The Refinitiv ESG score, a sustainability ranking to compare companies within an industry, is negative

How does the stock look chart-wise? (USD converted to euros) 📈📉

Let's now take a look at the chart of this company. The share price is currently just under €22. Here, too, is just directly an important zone. We are and just above an important support zone which is at 21.65€. We have also increasingly approached this in recent days. It is now important that we leave the zone and approach the first resistance. This is at 23.40 € and then comes directly the next at 24.60 €. If we take out these two resistances sustainably, the chances are good that we will continue to rise. The next target would then be at just under €29. If we also take out this resistance, we have for the time being nice space to the top. The first target would be at 34.20€ and then the high at 40.60€. Here, too, I am directly extremely curious how it continues here, which we are currently directly at a support zone, which can also already hold and the share can continue to rise. I'm very curious whether the share now also really turns here, or even further seeks the way down.

Your opinion: 🧐🤔

Now, of course, I would like to hear your opinions on these two shares in the comments.

What do you think of Clean Energy Fuels and Cassava Sciences and did you already know these companies?

Do you guys have one or both of these stocks maybe already in your portfolio?

Let me know in the comments.

This is of course not an investment advice but just my own opinion that I want to share with you!

Horny share.... About to buy

8. earningscall, wait until then?